Overview

Drug Screening Using IMD in Bladder Cancer

Status:
NOT_YET_RECRUITING
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This research study involves implanting up to 4 microdevices, each small enough to fit inside the tip of a needle, into a tumor. These devices will release microdoses (many thousands of times less than a treatment dose) of different cancer drugs into the tumor. After approximately 72 hours, the devices and small regions of surrounding tissue will be removed and studied. There will be a follow-up visit within 42 days of device removal to assess for potential safety issues or side effects.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Brigham and Women's Hospital
Treatments:
avelumab
Carboplatin
Cisplatin
enfortumab vedotin
erdafitinib
Gemcitabine
Methotrexate
Nivolumab
Paclitaxel
pembrolizumab
sacituzumab govitecan
Vinblastine